Status | Study |
RECRUITING |
Study Name: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma Condition: Cholangiocarcinoma Date: 2023-06-29 Interventions: Subjects randomized to receive tinengotinib will receive a starting dose of either 8 mg QD., self-administered orally QD in 28-day cycles. |
RECRUITING |
Study Name: Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC) Condition: Cholangiocarcinoma Date: 2021-07-09 Interventions: This is a study of the combination of platinum based chemotherapy (gemcitabine and cisplatin) and doublet immunotherapy (durvalumab and tremelimumab) |
Recruiting |
Study Name: Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy Condition: Cholangiocarcinoma Date: 2016-10-04 Interventions: Drug: INCB054828 INCB054828 once daily |
Active, not recruiting |
Study Name: Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma Condition: Cholangiocarcinoma Date: 2015-06-24 Interventions: Procedure: Radiofrequency ablation |
Active, not recruiting |
Study Name: Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma Condition: Cholangiocarcinoma Date: 2015-04-23 Interventions: Drug: Dasatinib Other Name: SPRYCEL ™ |
Recruiting |
Study Name: Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma Condition: Cholangiocarcinoma Date: 2015-03-10 Interventions: Drug: FOLFIRINOX Other Name: Second line treatment |
Active, not recruiting |
Study Name: Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma Condition: Cholangiocarcinoma Date: 2014-07-02 Interventions: Drug: Nab-Paclitaxel and Gemcitabine Nab-Paclitaxel will be administered first, at a dose of 125 mg/m |
Recruiting |
Study Name: A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma Condition: Advanced Cholangiocarcinoma Date: 2014-05-12 Interventions: Drug: BGJ398 Capsule for oral use |
Recruiting |
Study Name: Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma Condition: Cholangiocarcinoma Date: 2014-04-28 Interventions: Drug: CX-4945 Capsules adminis |
Withdrawn |
Study Name: VEGF Signaling Promotes Cell Growth and Metastasis in Extrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway (ECC) Condition: Extrahepatic Cholangiocarcinoma Date: 2014-03-31 Interventions: Procedure: surgical treatment all the patients in the study must have been treated by the surgery at the |